Supplementary Material for Publications

Lobritz, MA, AJ Marozsan, RM Troyer, and EJ Arts

"Natural Variation in the V3 Crown of Human Immunodeficiency Virus Type 1 Affects Replicative Fitness and Entry Inhibitor Sensitivity" 2007. J. Virol.

1. Fig. S1 - vif fitness assay.pdf

2. Fig. S2 - vif fitness Data NEW.pdf

3. Fig. S3 - Drug sensitivity Curves.pdf

Recent and Relevant Publications

*Some articles are made freely available by the publisher. Others are only by permission; please contact Dr. Eric Arts if asked for password.

1. Arts EJ, X Li, Z Gu, L Kleiman, MA Parniak, and MA Wainberg. 1994. Comparison of deoxyoligonucleotide and tRNA(Lys-3) as primers in an endogenous human immunodeficiency virus-1 in vitro reverse transcription/template-switching reaction. J. Biol. Chem. 269: 14672-80. (link)

2. Gu Z, RS Fletcher, EJ Arts, MA Wainberg, and MA Parniak. 1994. The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2', 3'-dideoxycytidine, 2',3'-dideoxy-3'-thiacytidine, and 2',3'-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro. J. Biol. Chem. 269: 28818-22. (link)

3. Gu Z, Y Quan, Z Li, EJ Arts, and MA Wainberg. 1995. Effects of non-nucleoside inhibitors of human immunodeficiency virus type 1 in cell-free recombinant reverse transcriptase assays. J. Biol. Chem. 270: 31046-51. (link)

4. Gu Z, EJ Arts, MA Parniak, and MA Wainberg. 1995. Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2',3'-dideoxycytidine 5'-triphosphate and other drugs. Proc. Natl. Acad. Sci. USA 92:2760-64. (link)

5. Arts EJ, M Ghosh, PS Jacques, B Ehresmann, and SF Le Grice. 1996. Restoration of tRNA3Lys-primed(-)-strand DNA synthesis to an HIV-1 reverse transcriptase mutant with extended tRNAs. Implications for retroviral replication. J. Biol. Chem. 271: 9054-61. (link)

6. Arts E.J and MA Wainberg. 1996. Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Antimicrob. Agents Chemother. 40: 527-40. (link)

7. Arts EJ, JP Marois, Z Gu, SF Le Grice, and MA Wainberg. 1996. Effects of 3'-deoxynucleoside 5'-triphosphate concentrations on chain termination by nucleoside analogs during human immunodeficiency virus type 1 reverse transcription of minus-strand strong-stop DNA. J. Virol. 70: 712-20. (link)

8. Li X, Y Quan, EJ Arts, Z Li, BD Preston, H de Rocquigny, BP Roques, JL Darlix, L Kleiman, MA Parniak, and MA Wainberg. 1996. Human immunodeficiency virus Type 1 nucleocapsid protein (NCp7) directs specific initiation of minus-strand DNA synthesis primed by human tRNA(Lys3) in vitro: studies of viral RNA molecules mutated in regions that flank the primer binding site. J. Virol. 70: 4996-5004. (link)

9. Arts EJ, SR Stetor, X Li, JW Rausch, KJ Howard, B Ehresmann, TW North, BM Wohrl, RS Goody, MA Wainberg, and SF LeGrice. 1996. Initiation of (-) strand DNA synthesis from tRNA(3Lys) on lentiviral RNAs: implications of specific HIV-1 RNA-tRNA(3Lys) interactions inhibiting primer utilization by retroviral reverse transcriptases. Proc. Natl. Acad. Sci. USA 93: 10063-8. (link)

10. Arts EJ, JT Miller, B Ehresmann, and SF Le Grice. 1998. Mutating a region of HIV-1 reverse transcriptase implicated in tRNA(Lys-3) binding and the consequences for (-)-strand DNA synthesis. J.Biol. Chem. 273: 14523-32. (link)

11. Arts EJ, ME Quiñones-Mateu, and JL Albright. 1998. Mechanisms of clinical resistance by HIV-1 variants to zidovudine (AZT) and the paradox of reverse transcriptase sensitivity. Drug Resist. Updates 1: 21-28.

12. Arts EJ, ME Quinones-Mateu, JL Albright, JP Marois, C Hough, Z Gu, and MA Wainberg. 1998. 3'-Azido-3'-deoxythymidine (AZT) mediates cross-resistance to nucleoside analogs in the case of AZT-resistant human immunodeficiency virus type 1 variants. J. Virol. 72: 4858-65..

13. Quinones-Mateu ME, JL Albright, A Mas, V Soriano, and EJ Arts. 1998. Pol gene quasi-species in patients infected with HIV-1 group O: An evolutionary and drug resistance study using genotypic and heteroduplex tracking analyses. J. Virol. 72:9002-15. (link)

14. Quinones-Mateu ME, JL Albright, V Torre, M Reinis, J Vandasova, M Bruckova, and EJ Arts. 1999. Molecular epidemiology of HIV-1 isolates from the Czech Republic. Identification of an env E subtype case. AIDS Res. Hum. Retroviruses. 15:85-89.

15. Quinones-Mateu ME and EJ Arts. 1999. Recombination in human immunodeficiency virus type-1 (HIV-1): Update and implications. AIDS Rev. 1: 89-100. (link)

16. Torre VS, AJ Marozsan, JL Albright, KR Collins, O Hartley, RE Offord, ME Quinones-Mateu, and EJ Arts. 2000. Variable sensitivity of CCR5-tropic HIV-1 to AOP-RANTES. J. Virol. 74: 4868-76. (link)

17. Garcia-Lerma JG, V Soriano, A Mas, ME Quionones-Mateu, EJ Arts, and W Heneine. 2000. Quantitation of HIV-1 group O plasma virus load by measuring reverse transcriptase activity. J. Clin. Microbiol. 38: 402-405. (link)

18. Collins KR, H Mayanja-Kizza, B Sullivan, ME Quinones-Mateu, Z Toossi, and EJ Arts. 2000. Greater HIV-1 quasispecies diversity in HIV-infected individuals with tuberculosis. J. AIDS. 24: 408-17. (link)

19. Quinones-Mateu ME, SC Ball, AJ Marozsan, VS Torre, JL Albright, G Vanham, G Van Der Groen, RL Colebunders, and EJ Arts. 2000. A dual infection/competition assay shows a correlation between ex vivo HIV-1 fitness and disease progression. J. Virol. 74: 9222-33 (link)

20. Quinones-Mateu ME, SC Ball, and EJ Arts. 2000. Role of human immunodeficiency virus type 1 group O in the AIDS pandemic. AIDS Rev. 2: 190-202. (link)

22. Menéndez-Arias L, A Abraha, ME Quiñones-Mateu, A Mas, M.J Camarasa, and EJ Arts. 2001. Functional characterization of chimeric reverse transcriptases with polypeptide subunits of highly divergent group O and M HIV-1 strains. J. Biol. Chem. 276: 27470-79. (link)

23. Marozsan AJ, VS Torre, M Johnson, JL Albright, ME Quinones-Mateu, and E.J Arts. 2001. Mechanisms involved in stimulation of human immunodeficiency virus type 1 replication by aminooxypentane RANTES. J. Virol. 75: 8624-38. (link)

24. Otieno MW, C Banura, E Katongole-Mbidde, JL Johnson, M Ghannoum, A Dowlati, R Renne, E Arts, C Whalen, M Lederman, and SC Remick. 2001. Therapeutic challenges of AIDS-related non-Hodgkin’s lymphoma in the United States and East Africa. J Natl Cancer Inst. 94:718-32.

25. Collins KR, ME Quinones-Mateu, M Wu, H Luzze, JL Johnson, C Hirsch, Z Toossi, and EJ Arts. 2002. Human immunodeficiency virus type 1 (HIV-1) quasispecies at the sites of Mycobacterium tuberculosis infection contribute to systemic HIV-1 heterogeneity. J. Virol. 76: 1697-1709. (link)

26. Quinones-Mateu ME and EJ Arts. 2002. HIV-1 Fitness: Implications on Disease Progression, Drug Resistance and Evolution of the Global Epidemic. 2002 HIV-1 Sequence Database and Compendium, Los Alamos, New Mexico. (link)

27. Collins KR, ME Quinones-Mateu, Z Toossi, and EJ Arts. 2002. Impact of tuberculosis on HIV-1 replication, diversity, and disease progression. AIDS Rev. 4: 165-176. (link)

28. Quinones-Mateu ME and E.J Arts. 2002. Fitness of drug resistant HIV-1: methodology and clinical implications. Drug Resist. Updates 5: 224-33. (link)

29. Quinones-Mateu ME, Y Gao, SC Ball, AJ Marozsan, A Abraha, and EJ Arts. 2002. In vitro intersubtype recombinants of human immunodeficiency virus type 1: comparison to recent and circulating in vivo recombinant forms. J. Virol. 76: 9600-13. (link)

30. Arts EJ and ME Quinones-Mateu. 2003. Sorting out the complexities of HIV-1 fitness. AIDS 17: 780-781. (link)

31. Ball SC, A Abraha, KR Collins, AJ Marozsan, HA Baird, ME Quinones-Mateu, A Penn-Nicholson, M Murray, N Richard, MA Lobritz, PA Zimmerman, T Kawamura, A Blauvelt, and EJ Arts. 2003. Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. J. Virol. 77: 1021-38. (link)

32. Marozsan AJ and EJ Arts. 2003. Development of a yeast-based recombination cloning/system for the analysis of gene products from diverse human immunodeficiency virus type 1 isolates. J. Virol. Methods 111:111-20. (link)

33. Gao Y, E Paxinos, J Galovich, R Troyer, H Baird, M Abreha, C Kityo, P Mugyenyi, C Petropoulos, and EJ Arts. 2004. Characterization of a subtype D human immunodeficiency virus type 1 isolate that was obtained from an untreated individual and that is highly resistant to nonnucleoside reverse transcriptase inhibitors. J Virol. 78:5390-401. (link)

34. Richard N, M Juntilla, A Abraha, K Demers, E Paxinos, J Galovich, C Petropoulos, CC Whalen, F Kyeyune, D Atwine, C Kityo, P Mugyenyi, and EJ Arts. 2004. High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1. AIDS Res Hum Retroviruses. 20:355-64.

35. Kawamura T, SE Bruse, A Abraha, M Sugaya, O Hartley, RE Offord, EJ Arts, PA Zimmerman, and A Blauvelt. 2004. PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes. J Virol. 78:7602-9. (link)

36. Marozsan AJ, E Fraundorf, A Abraha, H Baird, D Moore, R Troyer, I Nankja, and EJ Arts. 2004. Relationships between infectious titer, capsid protein levels, and reverse transcriptase activities of diverse human immunodeficiency virus type 1 isolates. J Virol. 78:11130-41. (link)

37. Bajunirwe F, I Massaquoi, S Asiimwe, MR Kamya, EJ Arts, and CC Whalen. 2004. Effectiveness of nevirapine and zidovudine in a pilot program for the prevention of mother-to-child transmission of HIV-1 in Uganda. Afr Health Sci. 4:146-54.

38. Baird HA, AJ Marozsan, MM Lederman, A Landay, D Mildvan, DR Kuritzkes, HA Kessler, and EJ Arts. 2005. Monitoring processed, mature Human Immunodeficiency Virus type 1 particles immediately following treatment with a protease inhibitor-containing treatment regimen. AIDS Res Ther. 2:2. (link)

39. Marozsan AJ, DM Moore, MA Lobritz, E Fraundorf, A Abraha, JD Reeves, and EJ Arts. 2005. Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry. J Virol. 79:7121-34.


Search PubMed for further references, citations, and any new publications.